Heron Therapeutics (NASDAQ:HRTX) Share Price Passes Above 200-Day Moving Average – What’s Next?

Heron Therapeutics, Inc. (NASDAQ:HRTX) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.37 and traded as high as $1.45. Heron Therapeutics shares last traded at $1.44, with a volume of 706,371 shares.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Heron Therapeutics in a report on Friday, January 9th. Zacks Research raised shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a report on Thursday. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, November 4th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Heron Therapeutics presently has a consensus rating of “Hold” and an average target price of $4.50.

Heron Therapeutics Price Performance

The company’s 50-day moving average price is $1.30 and its 200-day moving average price is $1.37. The company has a quick ratio of 1.78, a current ratio of 2.56 and a debt-to-equity ratio of 19.89. The firm has a market cap of $264.04 million, a price-to-earnings ratio of -16.00 and a beta of 1.28.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.03). The company had revenue of $38.21 million for the quarter, compared to analysts’ expectations of $39.03 million. On average, equities research analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Institutional Investors Weigh In On Heron Therapeutics

Large investors have recently bought and sold shares of the stock. PKS Advisory Services LLC purchased a new position in shares of Heron Therapeutics in the 3rd quarter valued at about $25,000. R Squared Ltd acquired a new stake in Heron Therapeutics in the second quarter valued at approximately $26,000. B. Riley Wealth Advisors Inc. purchased a new position in Heron Therapeutics in the second quarter worth approximately $26,000. Jones Financial Companies Lllp grew its holdings in Heron Therapeutics by 5,541.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 24,088 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 23,661 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Heron Therapeutics by 39.1% in the 4th quarter. SG Americas Securities LLC now owns 24,377 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 6,858 shares during the last quarter. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.